Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasisYun Zhang, Robert A. Weinberg, Joana Liu Donaher et al.|Nature Cell Biology|2022Cited by 130
May iron(III) complexes containing phenanthroline derivatives as ligands be prospective anticancer agents?Cristina P. Matos, Ceyda Açılan, Zelal Adıgüzel et al.|European Journal of Medicinal Chemistry|2019Cited by 45
Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma MultiformeFiliz Senbabaoglu, Tugba Bagcı-Önder, Ahmet Cingöz et al.|Cancer Biology & Therapy|2016Cited by 35
Exploiting epigenetic targets to overcome taxane resistance in prostate cancerBuse Cevatemre, Ceyda Açılan, İpek Bulut et al.|Cell Death and Disease|2024Cited by 20
Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survivalEzgi Ozyerli‐Goknar, Tugba Bagcı-Önder, Mehmet Gönen et al.|Cell Communication and Signaling|2023Cited by 12